185 related articles for article (PubMed ID: 33771722)
1. Pharmacokinetics of mometasone furoate delivered via two dry powder inhalers.
Vaidya S; Ziegler D; Tanase AM; Malmqvist U; Kanniess F; Hederer B; Hosoe M
Pulm Pharmacol Ther; 2021 Oct; 70():102019. PubMed ID: 33771722
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in patients with asthma.
Buhl R; Tanase AM; Hosoe M; Cao W; Demin I; Bartels C; Jauernig J; Ziegler D; Patalano F; Hederer B; Kanniess F; Tillmann HC
Pulm Pharmacol Ther; 2020 Jun; 62():101919. PubMed ID: 32387408
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of indacaterol and mometasone furoate delivered alone or in a free or fixed dose combination in healthy subjects.
Vaidya SS; Khindri S; Calder N; Machineni S; Hara H; Majumdar T; Febbraro S; Fuhr R; Woessner R
Pulm Pharmacol Ther; 2016 Apr; 37():30-6. PubMed ID: 26845343
[TBL] [Abstract][Full Text] [Related]
4. Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study.
van Zyl-Smit RN; Krüll M; Gessner C; Gon Y; Noga O; Richard A; de Los Reyes A; Shu X; Pethe A; Tanase AM; D'Andrea P;
Lancet Respir Med; 2020 Oct; 8(10):987-999. PubMed ID: 32653075
[TBL] [Abstract][Full Text] [Related]
5. Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/ indacaterol/glycopyrronium in patients with asthma.
Buhl R; Nikolaev I; Tillmann HC; Vaidya S; Bartels C; Jain M; Jauernig J; Kerstjens HAM
Pulm Pharmacol Ther; 2021 Oct; 70():102068. PubMed ID: 34329722
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of QMF149 in Japanese versus Caucasian subjects: an open-label, randomized phase I study.
Shimada S; Vaidya S; Khindri S; Tashiro N; Cheng Y; Hara H; Majumdar T; Woessner R; Furihata K; Kobayashi K
Int J Clin Pharmacol Ther; 2015 May; 53(5):398-407. PubMed ID: 25740265
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once-daily inhalation as a combination in healthy subjects.
Vaidya S; Jauernig J; Ethell B; Abdallah N; Machineni S; Drollmann A; Heudi O; Last S; Hahn M; Radhakrishnan R; Ignatenko S; Tillmann HC
Pulm Pharmacol Ther; 2020 Oct; 64():101964. PubMed ID: 33035700
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate administered as an inhaled fixed-dose combination in Japanese and Caucasian healthy subjects.
Inoue S; Vaidya S; Tillmann HC; Sakita Y; Machineni S; Heudi O; Furihata K
BMC Pulm Med; 2021 Jan; 21(1):18. PubMed ID: 33413291
[TBL] [Abstract][Full Text] [Related]
9. Lung Delivery of Indacaterol and Mometasone Furoate Following Inhalation of QMF149 in Healthy Volunteers.
Vaidya SS; Khindri S; Maahs S; Machineni S; Hara H; Juan A; Kaiser G
Clin Pharmacol Drug Dev; 2016 Jul; 5(4):285-95. PubMed ID: 27310329
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary disease.
Kosoglou T; Hubbell J; Xuan F; Cutler DL; Meehan AG; Kantesaria B; Wittmer BA
Int J Chron Obstruct Pulmon Dis; 2013; 8():107-16. PubMed ID: 23525511
[TBL] [Abstract][Full Text] [Related]
11. Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate.
Daley-Yates PT; Deans A; Mehta R; Sousa AR
Pulm Pharmacol Ther; 2022 Dec; 77():102171. PubMed ID: 36243386
[TBL] [Abstract][Full Text] [Related]
12. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study.
Kerstjens HAM; Maspero J; Chapman KR; van Zyl-Smit RN; Hosoe M; Tanase AM; Lavecchia C; Pethe A; Shu X; D'Andrea P;
Lancet Respir Med; 2020 Oct; 8(10):1000-1012. PubMed ID: 32653074
[TBL] [Abstract][Full Text] [Related]
13. Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial.
Beasley RW; Donohue JF; Mehta R; Nelson HS; Clay M; Moton A; Kim HJ; Hederer BM
BMJ Open; 2015 Feb; 5(2):e006131. PubMed ID: 25649209
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of inhaled once-daily low-dose indacaterol acetate/mometasone furoate in patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings.
Kornmann O; Mucsi J; Kolosa N; Bandelli L; Sen B; Satlin LC; D'Andrea P
Respir Med; 2020 Jan; 161():105809. PubMed ID: 32056721
[TBL] [Abstract][Full Text] [Related]
15. Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study.
Watz H; Hohlfeld JM; Singh D; Beier J; Diamant Z; Liu J; Hua S; Abd-Elaziz K; Pinot P; Jones I; Tillmann HC
Respir Res; 2020 Apr; 21(1):87. PubMed ID: 32295593
[TBL] [Abstract][Full Text] [Related]
16. A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma.
Brittain D; D'Andrea P; Gruen E; Hosoe M; Jain D; Jauernig J; Pethe A; Scosyrev E; Tanase AM; Tillmann HC
Adv Ther; 2022 Jun; 39(6):2365-2378. PubMed ID: 35072888
[TBL] [Abstract][Full Text] [Related]
17. Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON).
Gessner C; Kornmann O; Maspero J; van Zyl-Smit R; Krüll M; Salina A; Gupta P; Bostel S; Fucile S; Conde LG; Pfister P
Respir Med; 2020; 170():106021. PubMed ID: 32843164
[TBL] [Abstract][Full Text] [Related]
18. Lung function, pharmacokinetics, and tolerability of inhaled indacaterol maleate and acetate in asthma patients.
Miller D; Vaidya S; Jauernig J; Ethell B; Wagner K; Radhakrishnan R; Tillmann HC
Respir Res; 2020 Sep; 21(1):248. PubMed ID: 32967685
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of once-daily, single-inhaler, fixed-dose combination of mometasone/indacaterol/glycopyrronium in patients with asthma with or without persistent airflow limitation: Post hoc analysis from the IRIDIUM study.
Van Zyl-Smit RN; Kerstjens HA; Maspero JF; Kostikas K; Hosoe M; Tanase AM; D'Andrea P; Mezzi K; Brittain D; Lawrence D; Chapman KR
Respir Med; 2023 May; 211():107172. PubMed ID: 36906187
[TBL] [Abstract][Full Text] [Related]
20. Mometasone furoate dry powder inhaler: a once-daily inhaled corticosteroid for the treatment of persistent asthma.
Karpel JP; Nelson H
Curr Med Res Opin; 2007 Nov; 23(11):2897-911. PubMed ID: 17922978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
